Furthermore, decrease in CK18 was observed in Resmetiron, the first drug in the world to be approved as a treatment for MASH, suggesting its potential as a marker of therapeutic efficacy.49 This evidence concerns the gene KRT18 and metabolic dysfunction-associated steatohepatitis.